69 results
8-K
EX-99.1
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
4:32pm
Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; Leerink … Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 800-808-7525, ext. 6132, or by email
8-K
EX-1.1
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
4:32pm
or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S … . Department of State, the United Nations Security Council, the European Union, His Majesty’s Treasury of the United Kingdom, or other relevant sanctions
424B5
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
Prospectus supplement for primary offering
4:29pm
with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain “specified United
424B5
KALV
KalVista Pharmaceuticals Inc
14 Feb 24
Prospectus supplement for primary offering
5:13pm
, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held
8-K
EX-99.2
KALV
KalVista Pharmaceuticals Inc
13 Feb 24
Regulation FD Disclosure
6:55am
population that reflects my clinical practice,” said Danny Cohn, MD, PhD, Department of Vascular Medicine, University of Amsterdam, and principal investigator
S-8
EX-99.1
0zt3vzm bvt1wee1ax
20 Jun 23
Registration of securities for employees
4:13pm
8-K
EX-10.1
ey56dpawitx0 qh4gdy
14 Jun 23
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.1
yqm5h
27 Dec 22
Entry into a Material Definitive Agreement
6:42am
8-K
EX-99.1
irm0aw o6
11 Feb 21
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
4:18pm
8-K
EX-1.1
6udsjn
11 Feb 21
KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock
4:18pm
424B5
ju0k5vh02vblrvs0
11 Feb 21
Prospectus supplement for primary offering
4:11pm
424B5
u0wg4bqlgb2 3p
9 Feb 21
Prospectus supplement for primary offering
4:09pm
8-K
r0o7vs bw
27 Jan 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6:02am